Brent  Hatzis-Schoch net worth and biography

Brent Hatzis-Schoch Biography and Net Worth

With more than 20 years’ experience in the global pharmaceutical and biotechnology industry, Brent Hatzis-Schoch has held leadership positions at both commercial and development-stage companies.

Prior to joining Black Diamond as Chief Operating Officer, General Counsel, Brent was Senior Vice President (SVP), General Counsel and Corporate Secretary at Radius Health, Inc., a publicly traded commercial-stage biopharmaceutical company focused on the areas of osteoporosis and oncology. While at Radius, Brent had responsibility for the legal, intellectual property, contracts management, compliance, regulatory, and quality assurance functions, and helped build the company from a development-stage company to a commercial organization. Previously, he served as SVP and Chief Legal Counsel at Merz Pharma, an international healthcare company, in Frankfurt, Germany, where he had global responsibility for the legal, IP, and compliance functions. Brent began his legal career in private practice and later held senior legal positions in the U.S. and internationally, including as General Counsel to two publicly traded development-stage German biopharmaceutical companies, European legal counsel for Baxter International, and Associate General Counsel of Pharmacia Corporation.

Brent holds a Juris Doctor from George Washington University and was a Fulbright Scholar at the University of Cologne, Germany. He received his B.A. in International Relations from the University of Delaware.

What is Brent Hatzis-Schoch's net worth?

The estimated net worth of Brent Hatzis-Schoch is at least $63,263.46 as of May 12th, 2021. Mr. Hatzis-Schoch owns 12,478 shares of Black Diamond Therapeutics stock worth more than $63,263 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Hatzis-Schoch may own. Additionally, Mr. Hatzis-Schoch receives a salary of $683,290.00 as Insider at Black Diamond Therapeutics. Learn More about Brent Hatzis-Schoch's net worth.

How old is Brent Hatzis-Schoch?

Mr. Hatzis-Schoch is currently 59 years old. There are 7 older executives and no younger executives at Black Diamond Therapeutics. The oldest executive at Black Diamond Therapeutics is Dr. David M. Epstein Ph.D., Co-Founder & Director, who is 65 years old. Learn More on Brent Hatzis-Schoch's age.

What is Brent Hatzis-Schoch's salary?

As the Insider of Black Diamond Therapeutics, Inc., Mr. Hatzis-Schoch earns $683,290.00 per year. The highest earning executive at Black Diamond Therapeutics is Dr. David M. Epstein Ph.D., Co-Founder & Director, who commands a salary of $885,080.00 per year. Learn More on Brent Hatzis-Schoch's salary.

How do I contact Brent Hatzis-Schoch?

The corporate mailing address for Mr. Hatzis-Schoch and other Black Diamond Therapeutics executives is 139 MAIN STREET, CAMBRIDGE MA, 02142. Black Diamond Therapeutics can also be reached via phone at 617-252-0848 and via email at [email protected]. Learn More on Brent Hatzis-Schoch's contact information.

Has Brent Hatzis-Schoch been buying or selling shares of Black Diamond Therapeutics?

Brent Hatzis-Schoch has not been actively trading shares of Black Diamond Therapeutics during the past quarter. Most recently, Brent Hatzis-Schoch sold 4,078 shares of the business's stock in a transaction on Wednesday, May 12th. The shares were sold at an average price of $27.42, for a transaction totalling $111,818.76. Following the completion of the sale, the insider now directly owns 12,478 shares of the company's stock, valued at $342,146.76. Learn More on Brent Hatzis-Schoch's trading history.

Who are Black Diamond Therapeutics' active insiders?

Black Diamond Therapeutics' insider roster includes Brent Hatzis-Schoch (Insider), and Christopher Roberts (Insider). Learn More on Black Diamond Therapeutics' active insiders.

Are insiders buying or selling shares of Black Diamond Therapeutics?

In the last year, Black Diamond Therapeutics insiders bought shares 4 times. They purchased a total of 4,140,000 shares worth more than $20,488,600.00. In the last year, insiders at the sold shares 1 times. They sold a total of 25,000 shares worth more than $167,500.00. The most recent insider tranaction occured on October, 17th when Major Shareholder Growth N V Biotech bought 400,000 shares worth more than $936,000.00. Insiders at Black Diamond Therapeutics own 9.1% of the company. Learn More about insider trades at Black Diamond Therapeutics.

Information on this page was last updated on 10/17/2023.

Brent Hatzis-Schoch Insider Trading History at Black Diamond Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Sell4,078$27.42$111,818.7612,478View SEC Filing Icon  
4/12/2021Sell4,078$25.00$101,950.0012,478View SEC Filing Icon  
2/12/2021Sell4,078$27.23$111,043.9412,478View SEC Filing Icon  
1/12/2021Sell11,578$34.03$393,999.3412,478View SEC Filing Icon  
12/14/2020Sell4,078$34.95$142,526.107,078View SEC Filing Icon  
10/12/2020Sell4,078$32.70$133,350.607,078View SEC Filing Icon  
9/14/2020Sell4,078$31.04$126,581.127,078View SEC Filing Icon  
See Full Table

Brent Hatzis-Schoch Buying and Selling Activity at Black Diamond Therapeutics

This chart shows Brent Hatzis-Schoch's buying and selling at Black Diamond Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Black Diamond Therapeutics Company Overview

Black Diamond Therapeutics logo
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.07
Low: $4.99
High: $5.27

50 Day Range

MA: $4.29
Low: $2.67
High: $5.74

2 Week Range

Now: $5.07
Low: $1.43
High: $6.85

Volume

353,642 shs

Average Volume

602,701 shs

Market Capitalization

$262.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.65